---
title: "Tellgen plans to acquire controlling stake in Kanglu Bio to pursue synergies"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/251482507.md"
description: "Tellgen plans to acquire 72.8630% of Wuhan Kanglu Bio's shares for a transaction amount of 291 million yuan. Upon completion, Kanglu Bio will become its subsidiary. If conditions are met, it will further acquire 9.1370% of the shares in 2026 and 2027, ultimately reaching a shareholding of 82.00%. Kanglu Bio focuses on molecular diagnostics fields such as fluorescence in situ hybridization (FISH) and PCR, and this transaction is expected to bring synergies, enhancing the company's competitiveness and revenue growth"
datetime: "2025-08-04T14:11:02.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/251482507.md)
  - [en](https://longbridge.com/en/news/251482507.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/251482507.md)
---

# Tellgen plans to acquire controlling stake in Kanglu Bio to pursue synergies

According to the Zhitong Finance APP, Tellgen (300642.SZ) announced that the company plans to initially acquire 72.8630% of the shares of Wuhan Kanglu Biotechnology Co., Ltd. (referred to as "Kanglu Biotechnology"). After the company completes the acquisition of 72.8630% of Kanglu Biotechnology, it will become a subsidiary controlled by the company and included in the company's consolidated financial statements. In 2026 and 2027, if the preconditions stipulated in the agreement for this transaction are met, the company will further acquire 9.1370% of the shares of Kanglu Biotechnology held by Chen Gang and Xie Jun. After the completion of the aforementioned three-step acquisition, the company will hold a total of 82.00% of Kanglu Biotechnology.

The transaction amount for the acquisition of 72.8630% of Kanglu Biotechnology is RMB 291 million; in 2026 and 2027, if the preconditions stipulated in the agreement for this transaction are met, the company will further acquire 9.1370% of the shares of Kanglu Biotechnology held by Chen Gang and Xie Jun, with the transaction amount determined to be RMB 36.5481 million based on the aforementioned asset appraisal report as a pricing reference.

The announcement shows that Kanglu Biotechnology focuses on the expansion of the fluorescence in situ hybridization (FISH) niche and molecular diagnostics fields such as PCR, committed to achieving rapid, automated, and intelligent overall solutions for FISH detection. It has currently realized the rapid development, production, and sales of FISH reagents and automated detection equipment, possessing completely independent intellectual property rights for the FastProbe® rapid fluorescence in situ hybridization probe preparation technology. The products of Kanglu Biotechnology mainly include two categories: FISH and PCR. This transaction can achieve synergies in development strategy, market channels, products, and technology. At the same time, after the completion of the initial transaction, Kanglu Biotechnology will be included in the company's consolidated financial statements, which is expected to bring new revenue and profit growth points to the company and enhance the overall competitiveness of the company

### Related Stocks

- [300642.CN](https://longbridge.com/en/quote/300642.CN.md)

## Related News & Research

- [11:05 ETThe Church of Jesus Christ of Latter-day Saints Commits $25 Million to the UNICEF-led Child Nutrition Fund](https://longbridge.com/en/news/287088476.md)
- [CK Life Sciences shareholders pass AGM resolutions on director elections, mandates](https://longbridge.com/en/news/287189492.md)
- [‘Chicken wine’ ad banned for implying alcohol is therapeutic](https://longbridge.com/en/news/287029011.md)
- [New York Governor Signs Bills To Preserve Mandatory Vaccines](https://longbridge.com/en/news/286947583.md)
- [10:45 ETInventHelp Inventor Develops New Illuminated Display (SGM-649)](https://longbridge.com/en/news/286933598.md)